Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross-disciplinary translational hypothesis

Joseph M. Norris¹,² | Benjamin S. Simpson¹ | Alex Freeman³ | Alex Kirkham⁴ | Hayley C. Whitaker¹ | Mark Emberton¹,²

¹UCL Division of Surgery & Interventional Science, University College London, London, UK
²Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK
³Department of Pathology, University College London Hospitals NHS Foundation Trust, London, UK
⁴Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK

Correspondence
Joseph M. Norris, UCL Division of Surgery & Interventional Science, University College London, 3rd Floor, Charles Bell House, 43-45 Foley Street, London W1W 7TS, UK.
Email: joseph.norris@ucl.ac.uk

Funding information
Joseph M. Norris is funded by the Medical Research Council (MRC) (Grant Reference: MR/S00680X/1). Benjamin S. Simpson is funded by the Rosetrees Trust

Abstract
Pre-biopsy multiparametric magnetic resonance imaging (mpMRI) has transformed the risk stratification and diagnostic approach for suspected prostate cancer. The majority of clinically significant prostate cancers are visible on pre-biopsy mpMRI, however, there are a subset of significant tumors that are not detected by mpMRI. The radiobiological mechanisms underpinning mpMRI-visibility and invisibility of these cancers remain uncertain. Emerging evidence suggests that mpMRI-visible tumors are enriched with molecular features associated with increased disease aggressivity and poor clinical prognosis, which is supported by short-term endpoints, such as biochemical recurrence following surgery. Furthermore, at the histopathological level, mpMRI-visible tumors appear to exhibit increased architectural and vascular density compared to mpMRI-invisible disease. It seems probable that the genomic, pathological, radiological, and clinical features of mpMRI-visible and mpMRI-invisible prostate cancers are interrelated. Here, we propose a novel cross-disciplinary theory that links genomic and molecular evidence with cellular and histopathological appearances, elucidating both the mpMRI visibility and clinical status of significant prostate cancer.

KEYWORDS
Conspicuity theory, multiparametric MRI, prostate cancer

Abbreviations: 68Ga, Gallium-68; ADC, apparent diffusion coefficient; AUC, area under the curve; BCR, biochemical recurrence; BRCA, breast cancer gene; CCP, cell cycle progression; CD31, cluster of differentiation 31; CENPF, centromere protein F; CNA, copy number alterations; CT, computed tomography; DCE, dynamic contrast enhancement; DNA, deoxyribonucleic acid; DWI, diffusion-weighted imaging; E2F, E2 transcription factor; ECM, extracellular matrix; GC, genomic classifier; GDF15, growth differentiation factor 15; GPS, genomic prostate score; HR, hazard ratio; Ki67, Kiel protein 67; mL, milliliter; mpMRI, multiparametric magnetic resonance imaging; MYC, myelocytomatosis oncogene; n, number of patients; ng, nanogram; NICE, National Institute for Health and Care Excellence; OR, odds ratio; p, probability; PET, positron emission tomography; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; PTEN, phosphatase and tensin homolog; Rad, RAD homolog, DNA repair protein; RB1, retinoblastoma gene 1; T2W, T2-weighted imaging; tBCR, time to BCR; TRUS, transrectal ultrasound; TP53, tumor protein p53; UK, United Kingdom; VEGF, vascular endothelial growth factor; WNT-b, Wingless and Int-1 signaling pathway.

Joseph M. Norris and Benjamin S. Simpson joint first authors.

Hayley C. Whitaker and Mark Emberton joint senior authors.
1 | INTRODUCTION

The advent of multiparametric magnetic resonance imaging (mpMRI) likely represents the single most important change to the diagnostic pathway for men with suspected prostate cancer in the past century. The traditional strategy of measuring serum prostate-specific antigen (PSA) followed by systematic (semi-random) transrectal ultrasound (TRUS)-guided prostate biopsies is demonstrably poor as a diagnostic approach. This results in an excess number of non-image-guided biopsies, and ultimately, under-diagnosis of clinically significant cancer and over-diagnosis of clinically insignificant cancer. In contrast, pre-biopsy mpMRI has excellent diagnostic accuracy for clinically significant prostate cancer, identifying the majority of important tumors, even before a biopsy is performed. The diagnostic accuracy afforded by mpMRI is now reflected by inclusion of the technology into national and international guidelines for men with suspected prostate cancer, including those produced by the National Institute for Health and Care Excellence (NICE) in the UK.

However, approximately 10%-20% of clinically significant prostate cancers may appear invisible to mpMRI, producing understandable concern among clinicians and patients. The true clinical and oncological significance of mpMRI-invisible disease remains uncertain. In contemporary urological practice, mpMRI is now often used as a first-line triage tool to stratify those men that require a biopsy, and those that do not. If negative mpMRI is used as an indication to omit biopsy, then, there is a risk that men with mpMRI-invisible cancer may harbor undiagnosed significant disease, that may result in unfavorable clinical outcome. As a result, there has been a recent growing research interest in characterizing the nature of disease that is both detected and undetected by mpMRI.

We propose a novel hypothesis that provides potential explanation for the conspicuity of prostate cancer on mpMRI, linking evidence from molecular, histopathological, radiological, and clinical research fields.

2 | HYPOTHESIS: BRIDGING THE GAP BETWEEN BIOLOGY, PATHOLOGY, AND RADIOLOGY

Our hypothesis is that the positive mpMRI signal generated by visible prostate tumors is associated with multiple hallmarks of aggressive cancer, on a genetic, histopathological, and clinical level. Molecular evidence suggests that overexpression of proliferation-regulating genes and loss of tumor suppressor genes leads to increased tumor growth, which is noted in aggressive prostate cancer, including cribriform pattern disease. We believe that histopathologically, these genetic features result in larger volume tumors, with increased tumor epithelial cell density, and thus, a reduced stromal to epithelial ratio. Rapid tumor growth stemming from these genetic influences results in areas of hypoxia, triggering vascularization signaling cascades, further increasing microvessel density, tissue density, and tumor size.

Radiologically, it is plausible that these features contribute to tumor visibility in each of the constituent MRI sequences that form part of the mpMRI assessment. First, increased tumor size is likely to directly result in increased lesion conspicuity, as the larger the tumor volume, the more likely it is to be above the spatial resolution limits of mpMRI. This is likely to be true for all of the mpMRI sequences, especially the anatomic T2-weighted (T2W) sequence. Second, increased tumor tissue density manifests in restriction of movement of water molecules within malignant tissue, resulting in a stronger (more restricted) signal on the diffusion-weighted imaging (DWI) sequence and apparent diffusion coefficient (ADC) map. Finally, increased vascular density may render tumors more apparent on mpMRI due to higher concentrations of contrast agent (in this case, gadolinium) accumulating in the additional vascular spaces, thus, generating stronger signal on the dynamic contrast-enhanced (DCE) sequence.

Given these factors, it is plausible that larger, higher-grade tumors, enriched with unfavorable genetic features, would be associated with poor prognosis. This then supports the notion that mpMRI-visible cancer may confer a worse prognosis over mpMRI-invisible counterparts.

Our integrated theory is consistent with the natural pathogenesis of cancer and with a number of studies which have investigated the clinical, histopathological, and genetic features of disease conspicuity on mpMRI, as we describe in detail here.

3 | SUPPORTIVE EVIDENCE

The theory of prostate tumor visibility and invisibility on mpMRI should be addressed at three interconnected levels; the level of the organism, the level of tissue and cells, and the level of genetics.

3.1 | Organism-level: Clinical features of mpMRI-visible disease

In cancer biology, organism-level effects (ie, on patients with the disease) are ideally studied with long-term clinical outcome data. However, large longitudinal, mpMRI-correlated data sets are lacking to help clarify the association of clinical outcomes (such as, propensity for metastasis or prostate cancer-specific mortality) with the mpMRI visibility status of prostate tumors. Despite this, evidence demonstrating the correlation of mpMRI visibility with
shorter-term endpoints does exist, and we can make reasonable inferences from this data. Furthermore, as will be discussed in subsequent sections, clinical risk of particular mpMRI phenotypes may also be estimated from adjunctive tests, including genetic biomarkers and the pathological assessment of tumor grade.

A commonly cited short-term clinical endpoint in prostate cancer research is biochemical recurrence (BCR) following radical prostatectomy. Approximately 40% of patients with localized prostate cancer elect for radical prostatectomy as definitive therapy and a proportion of those that relapse after surgery go on to develop metastatic disease, eventually dying from prostate cancer.\(^{10-16}\) Therefore, it seems reasonable to assume a proportionality between BCR and longer-term endpoints.

A recent study evaluated the ability of mpMRI to predict BCR within 3 years in men undergoing radical prostatectomy for prostate cancer (n = 91). The authors found that higher presurgery mpMRI scores (ie, tumors with greater mpMRI visibility) were associated with a greater likelihood of BCR with an overall area under the curve (AUC) of 0.64 (95% CI: 0.55-0.73) indicating that tumor visibility on mpMRI has a good predictive ability to identify the most clinically aggressive tumors.\(^{17}\)

Park and colleagues also evaluated the ability of tumor visibility on the combined sequences of mpMRI to predict BCR in a cohort of patients (n = 282) that underwent radical prostatectomy for prostate cancer.\(^{18}\) Using multivariate Cox regression, they showed that tumor visibility on combined mpMRI sequences independently predicted increased likelihood of BCR (P = .047) in similar manner illustrated by both PSA and Gleason score. Indeed, apparent tumor presence on mpMRI carried the greatest hazard ratio (HR: 2.38) for BCR compared to Gleason score at biopsy (HR: 1.34) and PSA (HR: 1.05).\(^{18}\) Similar results were demonstrated by Hattori et al (n = 314) who showed that patients undergoing radical prostatectomy for prostate cancer with mpMRI-visible tumors carried the greatest risk for BCR (OR: 5.05, P = .031) in multivariate analysis compared to a Gleason score ≥ 8 at biopsy (OR: 4.85, P = .001) or a positive biopsy core ratio > 0.2 (OR: 3.19, P = .012).\(^{19}\) These results strongly suggest that conspicuity of cancer on mpMRI is an independent predictor of increased risk of disease recurrence following surgery, and as such, we might expect that a greater number of patients with mpMRI-visible tumors would be at higher risk of prostate cancer-specific mortality.

Obtaining reliable surrogate endpoints for mpMRI-correlated clinical outcomes in a non-prostatectomy setting remains complex, and studies investigating outcomes of mpMRI-directed active surveillance are few in number. However, a recent study from our own institution demonstrated that mpMRI-directed active surveillance (in which, re-biopsy was omitted if there was no identifiable mpMRI-visible lesion or radiological progression) showed that this imaging-based approach had comparable outcomes to standard, non-imaging-based practice, and that mpMRI-visible tumors that scored Gleason 3 + 4 had a reduced time to metastasis compared to similar mpMRI-invisible tumors.\(^{20}\)

### 3.2 Cellular-level: Histopathological features of mpMRI-visible disease

Through our recent systematic review of the pathological literature, we identified several interlinked histopathological hallmarks of tumor visibility on mpMRI.\(^{21}\) Compared to invisible disease, mpMRI-visible tumors appear to have higher Gleason grading,\(^{1,22}\) and increased tumor volume, cellular density,\(^{23,24}\) microvessel density, and proportion of unusual aggressive subtypes (such as, cribriform,\(^{9,25}\) and intraductal carcinoma). Furthermore, it appears that cellular heterogeneity (eg, presence of acinar and foamy cell types) was found more frequently in mpMRI-invisible disease compared to mpMRI-visible disease, which tended to have more homogeneous cell morphologies.\(^{9}\) Finally, prostate tumors arising in the transitional zone of the prostate also had reduced visibility on mpMRI compared to those originating in the peripheral zone, which had greater visibility.\(^{9}\)

These histopathological properties are informative, as Gleason grade, tumor volume, tumor cellular density, microvessel density, presence of cribriform and intraductal carcinoma, and tumors arising in the peripheral zone are all features associated with increased likelihood of disease recurrence following surgery.\(^{26-31}\) As such, these pathological observations further suggest that tumor mpMRI visibility may have genuine prognostic utility.

### 3.3 Genetic-level: The genetic landscape of mpMRI-visible disease

The genetic landscape that governs prostate tumor visibility on mpMRI is incompletely described. However, preliminary data are cohesive with our hypothesis and supports clinical and histopathological evidence, with enrichment of increased markers of disease aggressivity, including PTEN loss, CENPF expression, and higher genomic classifier scores, such as Oncotype and Decipher in mpMRI-visible tumors compared to invisible disease. In our recent systematic review of the genetic literature, we identified three studies that had large accompanying genetic databases that were suitable for further bioinformatic analysis.\(^{25,32,33}\) Through this approach, we found that key genetic changes associated with extracellular matrix (ECM) components appeared to have differential enrichment in mpMRI-visible disease, which may potentially explain several of the
described pathological features (such as, increased cellular density) found in conspicuous tumors.

Summation of the extant literature reveals three major themes that describe the integration of molecular evidence with histopathological and clinical data, further supporting our cross-disciplinary hypothesis. These themes are: hypoxia and angiogenesis, DNA damage and repair, and cell growth and proliferation.

### 3.3.1 Hypoxia and angiogenesis

Establishing blood supply through induction of vascularization is a crucial hallmark of malignancy and is a likely determinant of tumor mpMRI visibility and as such, is a key part our hypothesis. Perhaps the most well-known mediator of vascularization is VEGF, which encodes ligands that are involved in new blood vessel growth throughout embryonic and postnatal development. VEGF and microvessel density have been shown to associate with vascular perfusion in tumors on multiple imaging modalities, including computed tomography (CT), positron emission tomography (PET), and ultrasonography. VEGF expression has been observed to be enriched in mpMRI-visible prostate tumors and the response to anti-VEGF therapy can be monitored using mpMRI. VEGF expression and microvessel density additionally associates with tumor grade, metastasis and prognosis and this highlights a molecular component linking genetic, pathological, radiological, and clinical features of mpMRI-visible prostate cancer. These features are also shared with hypoxia-related signatures, which additionally appear to correlate with mpMRI-derived imaging features.

### 3.3.2 DNA damage and repair

Tumor hypoxia is known to downregulate DNA double strand break repair gene expression in prostate cancer cells such as: Rad51, Rad52, Rad54, BRCA1, BRCA2, leading to an increase in DNA damage. We previously identified DNA damage as a key element of the genetic determinants of tumor visibility on mpMRI, from previous studies that demonstrated that tumors with higher DCE values (ie, tumors that are visible on the contrast mpMRI sequence) had significantly higher deregulation of DNA repair-related genes, compared to tumors with lower DCE values. Li and colleagues also found that DNA damage repair pathway abnormalities were enriched in mpMRI-visible tumors. Together, these studies provide support for our hypothesis, given that pronounced DNA repair abnormalities found in mpMRI-visible disease are likely to contribute to an adverse clinical prognosis.

Recent evidence has revealed that the tumor suppressor gene, PTEN, is a critical regulator of the DNA damage response, specifically affecting double stranded break repair and nucleotide excision repair. PTEN loss has also been reported to be higher in mpMRI-visible tumors across multiple studies, further bolstering the concept of increased genetic risk in visible disease.

Finally, copy-number burden has been directly correlated with the expression of hypoxia-related genes and is known to correlate with poor prognosis. Kesch and colleagues found that copy number alterations (found in prostate tumors) were directly correlated to mpMRI and/or 68Ga-PSMA-PET/CT-derived imaging features, with an increased frequency of losses in chromosomal loci, such as 1p, 2q, 6p, 6q, 11q, 12p, 15q, and 22q and, less frequently, gains in 3q. These results were confirmed by Houlahan and colleagues who found a greater copy-number burden in mpMRI-visible tumors in a cohort which utilized a matched Gleason grade and tumor volume methodology to account for the potentially confounding effects of adverse histopathology. To further increase the strength of association between genetic features, tumor visibility and clinical outcome, it appears that several of these regions (in particular, 3q) have been associated with aggressive clinical features in prostate cancer, again providing support for our proposed hypothesis.

### 3.3.3 Cell growth and proliferation

Perhaps the most relevant molecular characteristic that links to radiobiological mechanisms of tumor conspicuity is that mpMRI-visible tumors appear to differentially express genes involved in cell growth and proliferation, when compared to mpMRI-invisible tumors (Figure 1). Bekscac and colleagues reported that pathways associated with cell cycle progression, specifically PI3K-AKT-mTOR, E2F, MYC target genes, and castration resistance genes (WNT-b) tended to have the highest enrichment in the most visible tumors. Furthermore, Li and colleagues undertook an impressive multiphase project, showing that mpMRI-visible tumors have increased expression of genes involved in mitotic cell cycle, protein folding, cell cycle, mitotic cell cycle process, and cell division. These included genes that encode proteins, such as CENPF and GDF15. As part of the in vivo phase of their investigation, they also showed that suppression of GDF15 resulted in reduced mpMRI visibility of tumors and decreased cell growth rate, lowering cell density of tumors, decreasing the vascular marker CD31 and proliferation marker Ki67. This increase in proliferative signaling in mpMRI-visible cancer potentially explains previous observational reports that showed increased tumor size, cellular density, and microvasculature in conspicuous disease.
4. CONFLICTING EVIDENCE

4.1 Organism-level: Conflicting clinical evidence

There are a small number of studies that have found that higher-grade tumors may be mpMRI-invisible, however, as yet, these have not been linked to long-term adverse clinical outcomes. Generally, these studies use pathological tumor grade to define clinical significance, and on the whole, lesion volume is not measured (or reported), which may suggest that the cited mpMRI-invisible tumors are below limits of spatial resolution, and that they may become visible if they grew in size. Nonetheless, given the established close relationship between Gleason grade and clinical outcome, these studies do, at present, contradict our hypothesis.

4.2 Cellular-level: Conflicting histopathological evidence

There are reports that certain aggressive prostate cancer subtypes, such as intraductal carcinoma and cribriform pattern disease, may have propensity for invisibility on mpMRI, which potentially undermines our hypothesis outlined here. However, there are also reports that contradict this evidence, to some extent. Cribriform pattern cancer is closely associated with Gleason grade (specifically, Gleason grade 4) and is noted to have increased mitotic rate, vascular invasion, tissue necrosis, and association with distant metastasis and disease-specific mortality, which are all features suggestive of mpMRI-visible disease. Furthermore, tumor necrosis and low oxygenation levels (features found in cribriform cancer) are related to tumor size, which is another strong correlate of tumor visibility. Overall, it seems that the small number of studies that report aggressive cribriform cancer to be an mpMRI-invisible entity may be outweighed by a higher number of studies which demonstrate that most tumors containing this cancer subtype are visible on mpMRI.

4.3 Molecular-level: Conflicting genetic evidence

A proportion of the extant genetic evidence suggests that our hypothesis does not hold true for all tumors, with some mpMRI-invisible cancers appearing to harbor potentially aggressive genes. However, there are studies that disagree with
this assertion. There are a small number of accounts that describe the genetic features of aggressive disease, such as copy number alterations in tumor suppressors \( RB1 \) and \( TP53 \), as well as \( MYC \) amplification may be present in mpMRI-invisible tumors. However, the potential effect of tumor suppressor mutations, in the context of an otherwise reassuring genetic environment on mpMRI-invisible disease, is unknown. Furthermore, on the whole, these alterations are unlikely to be sufficient, in isolation, to cause truly aggressive disease, and are predominantly a feature of mpMRI-visible tumors.

5 | THE CHALLENGE OF SIGNIFICANCE AND VISIBILITY THRESHOLDS

The concept of threshold management is intrinsic to the diagnosis and treatment of cancer and is important to consider when discussing our proposed hypothesis. Here, there are two thresholds to consider (Figure 2). First, the threshold for disease significance, in which there is a point on a theoretical spectrum (largely calibrated by tumor grade, size, and stage) in which a cancer, having begun as a small number of malignant cells, grows, and obtains oncological potential to spread and impact both quality and quantity of life (ie, becomes clinically significant). Second, a threshold for disease visibility, in which there is a point on a theoretical spectrum where a cancer acquires sufficient characteristics (such as, size, vascularity, or density) to become visible on mpMRI.

It seems possible that tumor visibility on mpMRI may occur before onset of clinical significance, which carries the potential risk of disease overtreatment. Our hypothesis and the extant evidence suggest this is unlikely, and in fact, mpMRI appears to enable avoidance of detection of insignificant disease, overall.

Alternatively, tumor visibility may occur at the point of development of clinical significance, which would represent the best-case scenario, providing diagnosis at the point at which treatment would be beneficial. This scenario supports our hypothesis, on multiple levels, however, the evidence used to construct this hypothesis is built on men with timely referral from primary care (eg, with PSA < 15 ng/mL), which may skew the mpMRI literature toward early detection.

Finally, tumor visibility may occur after the point of clinical significance has past, in which the window for disease curability may be lost. In this instance, there are small number of research groups that have suggested that mpMRI may overlook a significant number of high-grade prostate cancers, which clearly contradicts the hypothesis that we have described. However, these studies appear to be outliers, and key considerations of study methodology, population bias, definitions of significance, and quality of mpMRI acquisition and interpretation are likely to play a major role in their conclusions.

FIGURE 2  Potential scenarios for threshold alignment, between development of clinical significance (green line; from organ-confined through to metastases) and tumor visibility on mpMRI (blue line; from a small number of invisible cells to large visible tumors). Top: Tumor visibility may occur before onset of clinical significance, which risks overtreatment. Middle: Tumor visibility may occur at the point of development of clinical significance, which would represent an optimal treatment window. Bottom: Tumor visibility may occur after onset of clinical significance, which risks missing the window of curability.
Finally, an important observation in the field of prostate mpMRI is that not all mpMRI-visible lesions transpire to be cancerous at biopsy. High suspicion for significant cancer on mpMRI (ie, with an mpMRI-visible lesion) supports a higher likelihood of prostate cancer at biopsy, however, there remains a proportion of mpMRI-visible lesions that do not prove to be cancerous on pathology. Indeed, depending on center-experience and definitions of mpMRI visibility, almost 50% of suspicious lesions on mpMRI may transpire to be benign (or clinically insignificant disease) on biopsy.
At present, “false positivity” on mpMRI is commonly attributed to a number of possibilities. First, there is the possibility of under-sampling in which an mpMRI-visible lesion represents a truly significant tumor, however, this is missed by the biopsy needle. Second, a positive mpMRI signal may be generated by benign features that recreate the radiological appearance of cancer. For instance, in prostatitis and inflammation, there is a dense collection of benign cells which may restrict movement of water (thus producing increased signal on the DWI sequence) or perhaps result in increased permeability of blood vessels (increased signal on DCE sequence). Third, there may be other mpMRI signal-generating phenomena (eg, premalignant states) that have yet to be fully elucidated.

It seems possible that co-occurring benign pathological features that are sufficient to generate positive mpMRI signal (eg, inflammation) may also play a role in prostate conspicuity on mpMRI. For instance, mpMRI-visible cancers may have higher proportions of signal-producing co-occurring features compared to mpMRI-invisible disease, however, this has yet to be investigated.

7 | SUMMARY

The accumulation of recent evidence now creates a coherent scenario in which mpMRI-visible prostate cancers have tendency to higher histopathological grade, larger tumor volume, increased cellular density, higher microvessel density, and lower ratio of stroma to epithelia (Table 1). The molecular evidence also matches this picture, with many genetic attributes seeming to align with these features. It seems biologically plausible that features such as cell density are driven by the genes regulating cell-cell interactions, cell cycle, and proliferation, and that microvessel density may be governed by genes associated with angiogenesis and hypoxia-inducibility. These features are also consistently associated with histopathological features of disease aggressivity, including higher Gleason grade and the presence of cribriform pattern disease. Our hypothesis, in which mpMRI-visible tumors are likely to pose greater clinical risk than mpMRI-invisible tumors, is supported by all of these elements.

As mpMRI becomes an increasingly intrinsic part of our diagnostic armamentarium for suspected prostate cancer, there is a growing need to understand why certain tumors evade detection. Here, we have expounded a hypothesis underlying the conspicuity of prostate cancer on mpMRI, drawing important links between evidence found at each possible level. Future phases of this research should focus on testing this theory, particularly with longitudinal mpMRI-correlated data.

ACKNOWLEDGMENTS

This work was funded by the Medical Research Council (Grant Reference: MR/S00680X/1) and by the Rosetrees Trust.

CONFLICT OF INTEREST

Norris receives funding from the MRC. Simpson receives funding from the Rosetrees Trust. Whitaker receives funding from Prostate Cancer UK, the Urology Foundation and the Rosetrees Trust. Emberton, Freeman, and Kirkham have stock interest in Nuada Medical Ltd. Emberton receives funding from NIHR-i4i, MRC, Sonacare Inc, Trod Medical, Cancer Vaccine Institute and Sophiris Biocorp for trials in prostate cancer. Emberton is a medical consultant to Sonacare Inc, Sophiris Biocorp, Steba Biotech, GSK, Exact Imaging and Profound Medical. Travel allowance was previously provided from Sanofi Aventis, Astellas, GSK, and Sonacare. Emberton is a proctor for HIFU with Sonacare Inc and is paid for training other surgeons in this procedure.

AUTHOR CONTRIBUTIONS

All authors contributed equally to designing the research and writing the paper.

REFERENCES

1. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815-822.
2. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767-1777.
3. Wise J. NICE recommends MRI for suspected prostate cancer to reduce biopsies. BMJ. 2018;363:k5290.
4. Dasgupta P, Davis J, Hughes S. NICE guidelines on prostate cancer 2019. BJU Int. 2019;124:1. https://doi.org/10.1111/bju.14815
5. Radtke JP, Kuru TH, Boxler S, et al. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. J Urol. 2015;193:87-94.
6. Drost FH, Osses DF, Nieboer D, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4:CD012663.
7. Norris JM, Carmona Echeverria LM, Simpson BS, et al. Prostate cancer visibility on multiparametric magnetic resonance imaging: high gleason grade and increased tumour volume are not the only important histopathological features. BJU Int. 2020;126:237-239.
8. Norris JM, Simpson BS, Parry MA, et al. Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it’s time to take stock. BJU Int. 2019;125:340-342.
9. van Houdt PJ, Ghanbadi G, Schoots IG, et al. Histopathological features of MRI-invisible regions of prostate cancer lesions. J Magn Reson Imaging. 2020;51:1235-1246.
10. Adams S, Varkarakis IM. Defining prostate cancer risk after radical prostatectomy. *Eur J Surg Oncol*. 2014;40:496-504.

11. Petit JH, Chen MH, Loffredo M, Sussman B, Renshaw AA, D’Amico AV. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. *Cancer*. 2006;107:2180-2185.

12. Hricak H, Schoeder H, Pucar D, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. *Semin Oncol*. 2003;30:616-634.

13. Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE. Cause-specific mortality following radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2012;15:106-110.

14. Moul JW. Prostate specific antigen only progression of prostate cancer. *J Urol*. 2000;163:1632-1642.

15. Laufer M, Pound CR, Carducci MA, Eisenberger MA. Management of patients with rising prostate-specific antigen after radical prostatectomy. *Urology*. 2000;55:309-315.

16. Norris JM, Carmona Echeverria LM, Bott SRJ, et al. What type of prostate cancer is systematically overlooked by multiparametric MRI? An analysis from the PROMIS cohort. *Eur J Radiol*. 2020;20190373.

17. Jambor I, Falagario U, Ratnani P, et al. Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score. *J Magn Reson Imaging*. 2020;51:1075-1085.

18. Park JJ, Kim CK, Park SY, Park BK, Lee HM, Cho SW. Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy. *Am J Roentgenol*. 2014;202:W459-W465.

19. Hattori S, Kosaka T, Mizuno R, et al. Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy. *BJU Int*. 2014;113:741-747.

20. Stavrinides V, Giganti F, Trotz B, et al. Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study. *Eur Urol*. 2020;78:443-451.

21. Norris JM, Simpson BS, Parry MA, et al. Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis. *BMJ Open*. 2020;10:e034611.

22. Norris JM, Carmona Echeverria LM, Bott SRJ, et al. What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS cohort. *Eur Urol*. 2020;78:163-170.

23. Borren A, Groenendaal G, Moman MR, et al. Accurate prostate tumour detection with multiparametric magnetic resonance imaging: dependence on histological properties. *Acta Oncol*. 2014;53:88-95.

24. Miyai K, Mikoshi A, Hamabe F, et al. Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer. *Mod Pathol*. 2019;32:1536-1543.

25. Houlahan KE, Salmasi A, Sadun TY, et al. Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer. *Eur Urol*. 2019;76:18-23.

26. Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. *J Urol*. 2011;185:869-875.

27. Hong MK, Namdarian B, Corcoran NM, et al. Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. *Pathology*. 2011;43:138-142.

28. Lavallee LT, Breau RH, Preston MA, et al. The association between tumour density and prostate cancer recurrence following radical prostatectomy. *Can Urol Assoc J*. 2011;5:397-401.

29. Bono AV, Celato N, Cova V, Salvadori M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. *Prostate Cancer Prostatic Dis*. 2002;5:123-127.

30. Tom MC, Nguyen JK, Luciano R, et al. Impact of cribriform pattern and intraductal carcinoma on gleason 7 prostate cancer treated with external beam radiotherapy. *J Urol*. 2019;202:710-716.

31. Lee JJ, Thomas IC, Nolley R, Ferrari M, Brooks JD, Leppert JT. Biologic differences between peripheral and transition zone prostate cancer. *Prostate*. 2015;75:183-190.

32. Fraser M, Sabelnykova YY, Yamaguchi TN, et al. Genomic hallmarks of localized, non-indolent prostate cancer. *Nature*. 2017;541:359-364.

33. Li P, You S, Nguyen C, et al. Genes involved in prostate cancer progression determine MRI visibility. *Theranostics*. 2018;8:1752-1765.

34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144:646-674.

35. Ferrara N. Vascular endothelial growth factor. *Arterioscler Thromb Vasc Biol*. 2009;29:789-791.

36. Li JP, Meng QF, Sun CH, et al. Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. *World J Gastroenterol*. 2005;11:1287-1291.

37. Turkbey B, Kobayashi H, Ogawa M, Bernardo M, Choyke PL. Imaging of tumor angiogenesis: functional or targeted? *Am J Roentgenol*. 2009;193:304-313.

38. Lenkinski RE, Bloch BN, Liu F, et al. An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer. *MAGMA*. 2008;21:411-421.

39. Preda A, Novikov V, Moglich M, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. *J Magn Reson Imaging*. 2004;20:865-873.

40. Melegh Z, Oltean S. Targeting angiogenesis in prostate cancer. *Int J Mol Sci*. 2019;20:2676.

41. Sun Y, Williams S, Byrne D, et al. Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study. *Br J Radiol*. 2019;20190373.

42. Meng AX, Jalali F, Cuddihy A, et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer. *Radiother Oncol*. 2002;5:123-127.

43. Bono AV, Celato N, Cova V, Salvadori M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. *Prostate Cancer Prostatic Dis*. 2002;5:123-127.

44. Switlyk MD, Salberg UB, Geier OM, et al. PTEN expression in prostate cancer: a pilot study. *Am J Roentgenol*. 2019;212:1206–1214.

45. Lindberg SE, Lundell P, Sjostrand H, et al. Molecular hallmarks of multiparametric MRI findings. *Eur J Surg Oncol*. 2012;38:68038-68046.

46. Hong MK, Namdarian B, Corcoran NM, et al. Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. *Pathology*. 2011;43:138-142.

47. Lavallee LT, Breau RH, Preston MA, et al. The association between tumour density and prostate cancer recurrence following radical prostatectomy. *Can Urol Assoc J*. 2011;5:397-401.

48. Bono AV, Celato N, Cova V, Salvadori M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. *Prostate Cancer Prostatic Dis*. 2002;5:123-127.
48. Kesch C, Radtke JP, Wintsche A, et al. Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer. *Sci Rep.* 2018;8:16708.

49. Bek sac AT, Cumarasamy S, Falagario U, et al. Multiparametric magnetic resonance imaging features identify aggressive prostate cancer at the phenotypic and transcriptomic level. *J Urol.* 2018;200:1241-1249.

50. Chesnut GT, Vertosick EA, Benfante N, et al. Role of changes in magnetic resonance imaging or clinical stage in evaluation of disease progression for men with prostate cancer on active surveillance. *Eur Urol.* 2020;77:501-507.

51. Amin A, Scheltema MJ, Shnier R, et al. The magnetic resonance imaging in active surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies. *J Urol.* 2020;203:910-917.

52. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. *N Engl J Med.* 2018;382:917-928.

53. Bill-Axelson A, Holmberg L, Garmo H, et al. radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up. *N Engl J Med.* 2018;379:2319-2329.

54. Downes MR, Gibson E, Sykes J, Haider M, van der Kwast TH, Ward A. Determination of the association between T2-weighted MRI and gleason sub-pattern: a proof of principle study. *Acad Radiol.* 2016;23:1412-1421.

55. Coffey N, Schieda N, Cron G, Gulavita P, Mai KT, Flood TA. Multi-parametric (mp) MRI of prostatic ductal adenocarcinoma. *J Magn Reson Imaging.* 2015;41:1639-1645.

56. Truong M, Feng C, Hollenberg G, et al. A comprehensive analysis of cribriform morphology on magnetic resonance imaging/ultrasound fusion biopsy correlated with radical prostatectomy specimens. *J Urol.* 2018;199:106-113.

57. Schieda N, Coffey N, Gulavita P, Al-Dandan O, Shabana W, Flood TA. Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI). *Eur Radiol.* 2014;24:1349-1356.

58. Branca G, Ieni A, Barresi V, Tuccari G, Caruso RA. An updated review of cribriform carcinomas with emphasis on histopathological diagnosis and prognostic significance. *Oncol Rev.* 2017;11:317.

59. Kweldam CF, van der Kwast T, van Leenders GJ. On cribriform prostate cancer. *Transl Androl Urol.* 2018;7:145-154.

60. De Jaeger K, Merlo FM, Kavanagh MC, Fyles AW, Hedley D, Hill RP. Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis. *Int J Radiat Oncol Biol Phys.* 1998;42:717-721.

61. Tontilla PP, Ahtikoski A, Kuisma M, Paakko E, Hirvikoski P, Vaarala MH. Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer. *BJU Int.* 2019;124:992-998.

62. Parry MA, Srivastava S, Ali A, et al. Genomic evaluation of multiparametric magnetic resonance imaging-visible and -nonvisible lesions in clinically localised prostate cancer. *Eur Urol Oncol.* 2019;2:1-11.

63. Norris JM, Kasivisvanathan V, Allen C, et al. Exploring patient views and acceptance of multiparametric magnetic resonance imaging for the investigation of suspected prostate cancer (the PACT Study): a mixed-methods study protocol. *Methods Protoc.* 2020;3:1-11.

64. Norris JM, Kasivisvanathan V, Whitaker HC, et al. Investigating men's perceptions on the use of multiparametric MRI for the diagnosis of prostate cancer. *Eur J Surg Oncol.* 2019;45:2203.

65. Johnson DC, Raman SS, Mirak SA, et al. Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. *Eur Urol.* 2019;75:712-720.

How to cite this article: Norris JM, Simpson BS, Freeman A, Kirkham A, Whitaker HC, Emberton M. Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross-disciplinary translational hypothesis. *The FASEB Journal.* 2020;34:14150-14159. https://doi.org/10.1096/fj.202001466R